About Us

David  Aviezer has over 25 years of experience in biotechnology executive management, advancing products from early-stage research up to their approval by FDA and into commercialization. From 2002 through 2014 he served as President and Chief Executive Officer of Protalix BioTherapeutics, leading it to public listing on the New York Stock Exchange, and to receiving  FDA approval for a Gaucher disease drug and initiating the development of a Fabry disease drug, both rare genetic disorders. David has hands on experience in creating strategic partnerships and research agreements as well as raising capital in the private and public markets. Before joining Protalix, David served as General Manager of ProChon Biotech/CTI, a biotechnology company focused on rare growth disorders. Prior to that, he was a visiting scientist at the Medical Research Division of Cyanamid -Wyeth, now Pfizer,  in Pearl River, New York. David is also an adjunct Professor at Bar Ilan University. He seats on several boards and advisory panels in the national and private sectors. David holds a Ph.D in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from the Bar-Ilan University Business School.

Liora earned her PhD summa cum laude in Molecular and Cellular Biology from Bar‑Ilan University, Israel. She brings more than 20 years of experience in transforming innovative scientific concepts into successful late‑stage clinical products, with deep expertise in dermatology and orphan indications. Throughout her career, she has led global drug‑development programs and managed diversified product portfolios, consistently driving projects from early discovery through clinical execution until final approval.

Liora has extensive experience developing regulatory strategies for both the FDA and EMA and has served as the scientific lead for multiple NDA submissions. Prior to joining Kamari, she was the Head of Innovation and R&D at NeuroDerm, a Mitsubishi Tanabe Pharma company, where she directed multidisciplinary, multinational teams across complex development pipelines.

She is the author of more than 20 peer‑reviewed scientific publications.

Mr. Yarkoni is a finance executive and consultant with over 20 years of experience. He serves as a board member of several NASDAQ- and TASE-listed companies, including Bio Meat Foodtech, Isramco Inc., Tectona, and MIA Dynamics.

Prior to joining Kamari, he served as CEO and CFO of multiple TASE-listed high-tech companies, including Nexstage Therapeutics, Cannabotech, Continual, and Cannasure, and as M&A and Integration Manager at IBM Israel. He played a key role in scaling Storwize and led its acquisition by IBM. Earlier in his career, he served as a manager at Deloitte.

Mr. Yarkoni holds a BA in Business Administration and Accounting and an MBA with a concentration in Finance and Capital Markets.

Before joining Kamari, Dr. Michel served as Vice President and Program Lead for Solid Tumors at Karyopharm, where she led multiple solid tumor programs across strategic, medical, and operational domains. She brings over 25 years of experience in pharmaceutical R&D, spanning CRO and biotech environments, with international leadership roles in medical and clinical development. Her experience covers line and project management from early development through regulatory submission, including leadership of two sNDA submissions in sarcoma and endometrial cancer.

Dr. Michel has extensive experience managing cross-functional, cross-cultural, and geographically dispersed teams, with a proven ability to integrate scientific and medical evidence with business objectives.

Dr. Michel holds an MD from the Rappaport Faculty of Medicine, Technion – Israel Institute of Technology and an active medical license in Israel.

Dr. Almon joined Kamari Pharma Ltd. in July 2025 as its Chief Regulatory Officer. Dr. Almon is a Biotech executive, former Chief Development Officer and SVP at Protalix Ltd, with over 25 years of extensive experience in global protein drug development including strategic planning, management, and execution of more than 10 global clinical programs ranging from pre-clinical through successful international registration Phase 3 studies with track record of 2 global Marketing Authorization Approvals (FDA & EMA).

Dr. Almon brings experience in global cross-functional teams management and ability to integrate scientific rationale and medical evidence with business objectives.

In addition, Dr. Almon has experience in the development of tissue-based therapies as well as a strong background and work experience in Intellectual Property.

Dr. Almon holds a Ph.D. and an M.Sc. in Molecular Biology of Cancer from the Weizmann Institute of Science, a B.Sc. from the Hebrew University and has carried out Post-Doctoral research at the Hebrew University in molecular biology and  genetic engineering.  Dr. Almon further completed Directors and Officers course at the Reichman University.

Myriam Golembo is an expert in product development and regulatory affairs with over 20 years of experience in the biotech industry. She has led strategic regulatory interactions with the FDA, EMA, and the Israeli Ministry of Health, supporting programs from early development through clinical advancement and marketing approval, with a particular focus on rare diseases.

Prior to joining Kamari, she served as VP of Regulatory Affairs at BiomX, a publicly traded company developing microbiome-based therapies for chronic conditions, including cystic fibrosis, diabetic foot infections, and atopic dermatitis. In this role, she led global regulatory strategy and execution, overseeing multiple INDs and EMA submissions.

Earlier, she held senior leadership roles in regulatory affairs and clinical development across several biotech companies. Earlier in her career, she was Director of Product Development at Protalix Biotherapeutics, as part of the team advancing therapies for rare diseases, including Gaucher and Fabry disease.

Myriam holds a BSc and MSc in Immunology from the Hebrew University of Jerusalem and a PhD in Molecular and Developmental Genetics from the Weizmann Institute of Science.

David  Aviezer has over 25 years of experience in biotechnology executive management, advancing products from early-stage research up to their approval by FDA and into commercialization. From 2002 through 2014 he served as President and Chief Executive Officer of Protalix BioTherapeutics, leading it to public listing on the New York Stock Exchange, and to receiving  FDA approval for a Gaucher disease drug and initiating the development of a Fabry disease drug, both rare genetic disorders. David has hands on experience in creating strategic partnerships and research agreements as well as raising capital in the private and public markets. Before joining Protalix, David served as General Manager of ProChon Biotech/CTI, a biotechnology company focused on rare growth disorders. Prior to that, he was a visiting scientist at the Medical Research Division of Cyanamid -Wyeth, now Pfizer,  in Pearl River, New York. David is also an adjunct Professor at Bar Ilan University. He seats on several boards and advisory panels in the national and private sectors. David holds a Ph.D in Molecular Biology and Biochemistry from the Weizmann Institute of Science and an MBA from the Bar-Ilan University Business School.

John Doux is a board certified dermatologist and a fellow of the American Academy of Dermatology. Prior relevant board experience includes serving as chair of ValenzaBio (acquired by ACELYRIN) and as a director of Ceptaris Therapeutics (acquired by Actelion Pharmaceuticals), Palvella Therapeutics, and Lutris Pharmaceuticals. He also serves as a board trustee for the Pachyonychia Congenita Project. He received his B.S. and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow in the laboratory of Dr. David Woodley, and completed his clinical training at Brigham and Women’s Hospital and Stanford Medical Center. He subsequently earned an M.B.A. at the Wharton School of Business, where he was a Palmer Scholar. He has been an analyst at Palo Alto Investors since 2004. He was also a co-founder and prior board member of the Dermatology Summit and Dermatology Innovation Forum.

Ran Nussbaum is a managing partner and co-founder of Pontifax. The fund runs more than 50 portfolio companies around the Globe. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. In the past Ran served on Kite pharma BOD (sold to Gilead), cCAM Therapeutics (sold to Merck), and ArQule (sold to Merck), and Prevail Therapeutics (sold to Lilly). He also chaired Ocon Medical, Nasvax, Spearhead, and Biomedix. Currently, Ran sits on many of Pontifax’s portfolio companies including Eloxx Therapeutics (ELOX), and UroGen (URGN). Ran also serves as Keros Therapeutics (KROS) chairman of the board.

Ohad Hammer is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Step Pharma and Adcendo. Ohad obtained his MSc in Biology from Tel-Aviv University.

Alon Mor is a Partner at BRM and is responsible for life science investments. He brings from BRM an extensive background in healthcare as a senior executive with over 25 years of experience in the medical technology industry.

Prior to BRM, in 2004 Alon founded Aesthera Corporation – a Kleiner Perkins-backed innovator of light-based technologies for skin treatments. He was CEO and Chairman from Aesthera’s inception through its acquisition by Solta Medical in 2010. Prior to this, he was an executive in several medtech companies in Japan & US.

Professor of Molecular Dermatology and Centre Lead, Centre for Cell Biology and Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London and Honorary Consultant Dermatologist, Royal London Hospital, London, UK.

Prof. Edel O’Toole is a clinical academic at Barts and the London School of Medicine and Dentistry with an active research group working on rare genetic skin disease biology. Her main clinical interests are ichthyosis and palmoplantar keratodermas. She is the current clinical lead for the British Association of Dermatologists Dermatology and Genetic Medicine network. She is also on the steering committee of Pachyonychia Project and is actively involved in 100K Genomes, a gene discovery project within the NHS.

Professor of Medical Genetics and Director of INSERM department UMR 1163, Laboratory of Genetic skin diseases, University Paris Descartes – Sorbonne Paris Cité (France). Since 2009, he has been appointed full professor of Genetics in the department of Genetics at Necker hospital for sick children in Paris. He is the director of INSERM research laboratory on genetic skin diseases with an active research group working on rare genetic skin disease biology.  Professor Hovnanian one of the founders of the IMAGINE Institute for Genetic diseases which opened in 2014 at Necker hospital in Paris.

Prof Paller is the  Walter J. Hamlin Professor and Chair of Dermatology at Northwestern University, and a renowned physician-scientist in pediatric dermatology. She has authored nearly 600 peer-reviewed publications and edited leading textbooks, including Hurwitz’s Clinical Pediatric Dermatology and Fitzpatrick’s Dermatology in General Medicine. Dr. Paller leads NIH-funded laboratory and clinical research programs and has directed the Pediatric Dermatology Clinical Trials Unit for over 30 years, serving as lead investigator on landmark trials in atopic dermatitis, psoriasis, and genetic skin disorders. Her research includes nanotherapy-based gene regulation, biomarkers in atopic dermatitis  and ichthyosis, and the development of validated patient-reported outcome tools for children. She has served as president of multiple major societies and is currently President of the International Society for Pediatric Dermatology. Dr. Paller has received numerous top international awards recognizing her leadership, scientific impact, and mentorship.